Navigation Links
Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization

Proprietary technology identifies small molecule JAK2 and Pim kinase


SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced data as part of a series of presentations at the 2007 AACR-NCI-EORTC International Conference that describe how its proprietary CLIMB technology was used in lead development and design of small molecule JAK2 and Pim kinase inhibitors (Posters C200 and C208).

Poster C200 (Abstract No. 907)

Effect of small molecule inhibitors of JAK2 kinase on modulating signaling cascades downstream of cytokine receptors

Janus kinases (JAKs) are critical to a number of intracellular signaling pathways. Dysregulation of JAK2 signaling has been implicated in myoproliferative disorders, leukemia, lymphoma and various solid tumors. Utilizing CLIMB, SuperGen's proprietary technology, scientists used a JAK2 crystal structure to build several models that were made into a substrate for screening a large, virtual small molecule library. This process generated a subset of leads that were screened using in silico algorithms to identify "druggable" candidates to pursue.

Poster C208 (Abstract No. 985)

A small molecule inhibitor of Pim-1 kinase with activity in both hematological and solid tumor malignancies

Pim-1 kinase is involved in signaling pathways as a potent inhibitor of programmed cell death (apoptosis). Pim-1 is over expressed in many cancer types, including AML, CML, bladder and oral cancers. Scientists used SuperGen's CLIMB technology to build a model that allowed for the prediction of small molecule inhibitors. Leads were screened to identify those with inhibitory activity with low nanomolar IC50 concentrations. Data support further development of the lead compounds in liquid and solid tumors.

Copies of the poster presentations will be available in the pipeline section of SuperGen's Web site

"With our CLIMB technology we are able to decrease cycle times while identifying the most druggable candidates," said Dr. James S. Manuso, President and Chief Executive Officer. "This allows us to move at a rapid pace to select candidates that can be advanced into clinical trials."

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.


Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications & Manager, Investor Relations

Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail:


SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
5. President Bush Ignores Americas Plea for Support of Stem Cell Research
6. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
7. Diabetes drug supported by Mexican Diabetes Federation
8. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
11. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group ... Tournament held on June 20th at the Woodmont Country Club at 1201 Rockville ... an organization dedicated to helping service members that have been wounded in battle and ...
Breaking Medicine News(10 mins):